How to buy BridgeBio Pharma stock

BridgeBio Pharma, Inc is a biotechnology business based in the US. BridgeBio Pharma shares (BBIO) are listed on the NASDAQ and all prices are listed in US Dollars. BridgeBio Pharma employs 385 staff and has a trailing 12-month revenue of around 0.00.

BridgeBio Pharma share price

Use our graph to track the performance of BBIO stocks over time.

BridgeBio Pharma shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$26.17 - $73.50
50-day moving average	$59.85
200-day moving average	$57.38
Wall St. target price	$84.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-10.90

Buy BridgeBio Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy BridgeBio Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BridgeBio Pharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BridgeBio Pharma financials

Revenue TTM	$8.2 million
Gross profit TTM	$8.2 million
Return on assets TTM	-44.42%
Return on equity TTM	-173.15%
Profit margin	0%
Book value	$3.92
Market capitalisation	$8.3 billion

TTM: trailing 12 months

Shorting BridgeBio Pharma shares

There are currently 10.7 million BridgeBio Pharma shares held short by investors – that's known as BridgeBio Pharma's "short interest". This figure is 2% up from 10.5 million last month.

There are a few different ways that this level of interest in shorting BridgeBio Pharma shares can be evaluated.

BridgeBio Pharma's "short interest ratio" (SIR)

BridgeBio Pharma's "short interest ratio" (SIR) is the quantity of BridgeBio Pharma shares currently shorted divided by the average quantity of BridgeBio Pharma shares traded daily (recently around 813663.65019011). BridgeBio Pharma's SIR currently stands at 13.15. In other words for every 100,000 BridgeBio Pharma shares traded daily on the market, roughly 13150 shares are currently held short.

However BridgeBio Pharma's short interest can also be evaluated against the total number of BridgeBio Pharma shares, or, against the total number of tradable BridgeBio Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BridgeBio Pharma's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 BridgeBio Pharma shares in existence, roughly 70 shares are currently held short) or 0.138% of the tradable shares (for every 100,000 tradable BridgeBio Pharma shares, roughly 138 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BridgeBio Pharma.

Find out more about how you can short BridgeBio Pharma stock.

BridgeBio Pharma share dividends

We're not expecting BridgeBio Pharma to pay a dividend over the next 12 months.

BridgeBio Pharma overview

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.

Frequently asked questions

• What percentage of BridgeBio Pharma is owned by insiders or institutions?

  Currently 5.468% of BridgeBio Pharma shares are held by insiders and 80.035% by institutions.

• How many people work for BridgeBio Pharma?

  Latest data suggests 385 work at BridgeBio Pharma.

• When does the fiscal year end for BridgeBio Pharma?

  BridgeBio Pharma's fiscal year ends in December.

• Where is BridgeBio Pharma based?

  BridgeBio Pharma's address is: 421 Kipling Street, Palo Alto, CA, United States, 94301

• What is BridgeBio Pharma's ISIN number?

  BridgeBio Pharma's international securities identification number is: US10806X1028

• What is BridgeBio Pharma's CUSIP number?

  BridgeBio Pharma's Committee on Uniform Securities Identification Procedures number is: 10806X102